Actively Recruiting
Phase 2 Study of Epcoritamab and Rituximab for Treating Untreated Follicular Lymphoma
Led by Reid Merryman, MD · Updated on 2026-05-22
100
Participants Needed
6
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how effective and safe the combination of two drugs, rituximab and epcoritamab, is for treating patients with follicular lymphoma FL who have not received previous treatments. This open-label, multicenter phase II study focuses on patients with untreated FL, aiming to understand how epcoritamab, a T-cell bispecific antibody, works together with rituximab, a monoclonal antibody approved for FL, to target and kill lymphoma cells. The study is supported by Genmab and AbbVie, with Genmab providing funding and the study drug epcoritamab. Participants receive treatment over approximately 9 to 10 months. The treatment involves cycles where rituximab is given on specific days in cycle 1 through intravenous infusion, and epcoritamab is administered by subcutaneous injection on multiple days across cycles 1 to 9. PETCT scans are performed at baseline and after certain treatment cycles to monitor response. After treatment, surveillance imaging occurs at 13, 18, and 24 months, followed by follow-up visits for up to 5 years to observe long-term effects. Throughout the study, participants undergo evaluations including blood tests, bone marrow biopsies, and imaging scans. Researchers measure metabolic response rates at the end of treatment and monitor safety by tracking side effects like cytokine release syndrome and neurotoxicity. The study also follows participants for up to 10 years to assess long-term outcomes such as disease progression, survival rates, and any histological transformation. This comprehensive monitoring helps assess the combined treatments impact and safety profile in patients with follicular lymphoma.
CONDITIONS
Brief Title
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Research Team
R
Reid Merryman, MD
H
Heather A Walker, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here